May 4, 2023 07:32 AM EDTUpdated 08:12 AM
R&D

Io­n­is chops two PhII pro­grams in acromegaly and be­ta tha­lassemia

Lei Lei Wu

News Reporter

Io­n­is Phar­ma­ceu­ti­cals is cut­ting two pro­grams — a can­di­date for acromegaly and one for be­ta tha­lassemia — ac­cord­ing to its fist quar­ter earn­ings re­port Wednes­day af­ter­noon. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times